BridgeBio Pharma has dosed the first participant in the Phase I/II clinical trial of BBP-398 in combination with Bristol Myers Squibb’s Opdivo (nivolumab) in non-small cell lung cancer (NSCLC) patients with KRAS mutations.

The Phase I trial has been designed for assessing the pharmacodynamics, tolerability, preliminary efficacy, pharmacokinetics, and safety of the investigational SHP2 inhibitor BBP-398 along with Opdivo. It involves two parts, Phase Ia dose escalation and Phase Ib dose expansion.

Patients with advanced NSCLC with a KRAS mutation who were not responsive to standard of care will be enrolled in both the dose escalation and expansion periods.

The dose expansion part will assess the antitumor activity of the combination of BBP-398 and Opdivo.

BridgeBio Pharma expects that the combination therapy will address the serious unmet need for patients with KRAS-mutated NSCLC as well as other advanced solid tumours with KRAS mutations, if approved.

BridgeBio Pharma oncology chief scientific officer Eli Wallace said: “SHP2 has been shown to be a key regulator of both tumour and immune cell signalling. In KRAS mutant tumours, SHP2 promotes survival, proliferation, and decreased immunogenicity by driving the active form of KRAS, while in immune cells, it associates with PD-1 which leads to immunosuppression in the tumour microenvironment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“By partnering with Bristol Myers Squibb on this trial, we hope to show that targeting PD-1 with a two-prong approach can unlock the potent benefits of immunotherapy against this cancer and provide new treatment options for patients who need them.”

The company expects to receive the initial Phase I data from the ongoing BBP-398 trial this year.